Categories: All postsAnalysts

Imaflex has 86 per cent upside, Beacon Securities says

Beacon Securities’ Ahmad Shaath says more competition in the Quebec market is hurting Imaflex Inc.’s (TSXV:IFX) margins, although he’s encouraged by signs of progress in expanding its sales pipeline for Shine N’Ripe XL crop protection film.

On Monday, the analyst maintained his “Buy” recommendation but lowered his price target from $2.00 to $1.75, representing a projected return of 86 per cent at the time of publication.

Makers of agricultural mulch films and polyethylene films for packaging, Montreal-based Imaflex announced its second quarter 2018 financial results on Monday, featuring $21.9 million in revenue, down from $24.1 million in Q2 of 2017.

“Although year-over-year results were somewhat muted in the second quarter, current business fundamentals are looking stronger,” said Joe Abbandonato, President and CEO, in a press release. “We just received another C$0.9 million citrus film order and we are beginning to see sales momentum in our core flexible packaging business. As well, we are setting the stage for future growth, recently securing C$10 million of equipment financing to fund business expansion.”

Shaath says the $21.9 million topline was slightly above his expected $21.7 million, while IFX’s adjusted EBITDA loss of $1.4 million came in below his forecast of $2.2 million, due, he says mostly to weaknesses in gross margins caused by a new entrant in the Quebec market.

“The company saw a good portion of the ‘defected’ customers come back towards the end of Q2/FY18, largely due to its better manufacturing quality and quick turnaround times, which should help margins bounce back,” says Shaath in an update to clients on Monday. “We expect these conditions to improve in FY19 (revision of -100bps to our previous margin assumptions). On the citrus film front, we made no major changes to our revenue and margin assumptions as we expect IFX to continue to be successful in landing repeat business from its existing customers as well as convert 1-2 “in trial” customers,” he said.

Shaath says he continues to view IFX as a relatively cheap play in the flex-packaging sector with potential for significant upside from its agricultural tech products, valuing IFX at 6.3x his FY19 EBITDA estimate.

The analyst has revised his projections, now calling for revenue and Adj. EBITDA in FY18 of $82.5 million (was $82.8 million) and $7.0 million (was $8.7 million), respectively, and revenue and Adj. EBITDA in FY19 of $97.7 million (was $99.0 million) and $9.4 million (was $10.6 million), respectively.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ifx
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

8 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

14 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

15 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

16 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago